In the past two years, the Food and Drug Administration has approved two novel Alzheimer’s therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.
PBMs aren’t opening access to lower-cost biosimilars. Reform is needed now
The Federal Trade Commission presents on Thursday its interim staff report, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” It
August 1, 2024